Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

FTC CONSUMER PROTECTION, COMPETITION BUREAU CHIEFS appointed by new Federal Trade Commission Chairman Daniel Oliver. The new director of the Bureau of Consumer Protection is William MacLeod, who is currently director of FTC's Chicago regional office. Before moving to head the field office, MacLeod was an advisor to former FTC Chairman James Miller. Jeffrey Zuckerman is the new director of the Bureau of Competition. Since 1984, he has been chief of staff to the chairman of the U.S. Equal Employment Opportunity Commission. Prior to that he was special assistant to the attorney general in charge of the antitrust division of the Justice Department The two appointments are effective July 7. The positions have been filled on an acting basis since last November when acting FTC Chairman Terry Calvini named Amanda Pedersen and Walter Winslow to acting directors of the Bureau of Consumer Protection and Bureau of Competition, respectively. The transition of the chairmanship to Oliver enabled FTC to fill the slots on a permanent basis. Robert Paul was also named general counsel of FTC, effective Sept. 3. Paul is a partner in the Boston firm of Goodwin, Procter & Hoar. Prior to joining that firm, he was a trial attorney in the Justice Dept.'s Antitrust Division from 1967 to 1969. March Tiffany has served as acting general counsel since November, filling in for John Carley, who moved to the Office of Management & Budget.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts